Derivatives and securities exchange network Cboe Global Markets has made changes and new appointments to its senior leadership team, including the appointment of Catherine Clay to the new role of Global Head of Derivatives.
Falcon Investment Management Ltd, a UK-based multi-manager hedge fund platform, has partnered with alternative investment fintech FundFront for the launch of its upcoming emerging manager platform.
Multi-strategy hedge fund major Millennium Management has appointed Gideon Mann as its new Global Head of AI, Technology, with responsibility for building out a new team to help the firm “navigate the AI space”.
A new change in US Securities and Exchange Commission disclosure rules is cutting the time limit for activist hedge funds and other investors to report when they have acquired 5% or more of a company’s stock, according to a report
Proposed regulations from the Asset Management Association of China which will impact the country’s RMB6tn hedge fund industry have prompted a pushback from several funds over concerns that they will increase operational costs and lessen competitiveness, according to a report
Caius Capital, an alternative investment manager focused on distressed and special situations, led a group of creditors in agreeing to provide a financing package aimed at boosting the balance sheet of the UK’s Metro Bank, according to a report by
Propellant.digital, an analytics FinTech that captures and analyses global trading activity to drive business decisions, has made a senior addition to its team with the appointment of Oliver Haste as Head of EMEA Product.
Odey Wealth Management, a UK and Guernsey based former subsidiary of Odey Asset Management, is to close and return assets to clients in the wake of the multiple allegations of sexual assault and harassment made against the firm’s founder Crispin
Polaris Capital Management has promoted Jason Crawshaw to Executive Vice President. He will now serve in an executive management position while retaining his existing role as a Portfolio Manager at the firm.
Bets that US regulators would be unable to stop Amgen Inc from completing its $28bn acquisition of Horizon Therapeutics have yielded big gains for hedge funds Pentwater Capital Management, HBK Investments and Farallon Capital Management, according to a report by
